-
[show abstract]
[hide abstract]
ABSTRACT: In this paper the case of hyperparathyroidism with clinical features of multicentric giant cell tumor of bone is reported. The pathological, radiological and clinical differences between these two entities are discussed.
Przegla̧d lekarski 02/1998; 55(10):549-51.
-
[show abstract]
[hide abstract]
ABSTRACT: The aim of this study was to assess effects of second-line chemotherapy in metastatic breast cancer via determination of CA 15-3 marker. Analysis included 73 women, in whom distant metastases were diagnosed within 14-72 months (median: 43) after the completion of basic therapy. Average age of patients at primary diagnosis was 50.7 +/- 12.6 years. Dominant sites of metastases were: liver (27 patients) and lungs (24 patients). Serum CA 15-3 was examined immunoenzymatically at diagnosis of distant metastases and then after 2-4 cycles (median 4) of anthracycline-based chemotherapy. Changes of mean CA 15-3 values correlated with the UICC response criteria. There was a significant fall in mean levels of CA 15-3 after treatment in patients with complete (p < 0.004) and partial regression of metastatic lesions (p < 0.03). Stabilization and progression of the disease were associated with raise in CA 15-3 mean values, but the difference was significant only in the latter group (p < 0.02). In 31 out of 39 patients (79.5%) with regressive disease (complete and partial response) CA 15-3 levels decreased by at least 25% after treatment. Nine of 11 (81.8%) patients with stable disease had the antigen concentrations that did not vary by more than +/- 25% of the initial CA 15-3 value. CA 15-3 levels raised by at least 25% in 22 out of 23 (95.7%) cases with progressive breast cancer. Overall, CA 15-3 variations correlated with the disease status in 62 (84.9%) patients. These findings confirmed the usefulness of CA 15-3 determinations in evaluating the efficacy of second-line chemotherapy in patients with advanced breast cancer.
Polskie archiwum medycyny wewnȩtrznej 04/1997; 97(4):343-50. · 1.37 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: In the present study results of serum CA 15-3 immunoassay obtained at diagnosis in 231 breast cancer women (average age: 54.6, range: 27-87 years) were correlated with prognostic factors of the disease; the cut-off level was established at 30.0 U/ ml. As a result, elevated mean values of serum CA 15-3 as well as positivity rates of the test were significantly associated with more advanced stage of breast cancer, presence of distant metastases, involvement of four and more axillary lymph nodes, high BLOOM and RICHARDSON grade [3], low contents of estrogen (ER) and progesterone (PgR) receptors. Although serum CA 15-3 concentrations should be paralleled the increasing tumor size, the difference being significant only for the proportion of positive results. Our findings suggest that pretreatment levels of CA 15-3 antigen represent the breast cancer extent and reflect the cell differentiation and aggressiveness of the tumor. We conclude that pretreatment concentrations of CA 15-3 antigen may be useful as a prognostic factor in breast cancer patients.
Neoplasma 02/1996; 43(4):225-9. · 1.44 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Serum CA 15-3 concentrations were determined using sandwich enzyme immunoassay in 430 women: 214 breast cancer patients prior to any therapy, 161 patients with benign breast diseases, and 55 healthy controls; the cut-off limit was established at 30.0 U/ml. In breast cancer patients, CA 15-3 levels positively correlated with negative prognostic factors: higher tumor size (p < 0.001), positive axillary lymph nodes (p < 0.02), high histological grade (p < 0.01), low contents of estrogen (p < 0.05) and progesterone (p < 0.006) receptors. However serum CA 15-3 values raised in parallel with clinical stage of breast cancer, the difference was not significant. The overall diagnostic sensitivity and specificity of the test were 24.3% and 94.9%, respectively. The mean serum CA 15-3 values and the percentage of positive results in breast cancer patients were significantly higher as compared to benign breast diseases group (27.52 +/- 27.01 vs. 16.75 +/- 8.43, p < 0.001; 24.3% vs. 5.6%, p < 0.001, respectively) as well as to healthy controls (27.52 27.01 vs. 13.37 +/- 6.51, p < 0.001; 24.3% vs. 3.6%, p < 0.01, respectively). The sensitivity of the CA 15-3 test is low and thus not suitable for the differential diagnosis of breast lumps. Our data suggest potential prognostic value of pretreatment CA 15-3 assays in breast cancer patients.
Przegla̧d lekarski 01/1996; 53(11):788-92.
-
[show abstract]
[hide abstract]
ABSTRACT: In this article the results of molecular marker p53 examinations were presented in relation to the following established breast cancer prognostic factors: age, histologic type, histologic grade, lymph node involvement, tumor size as well as estrogen a progesterone receptor status. Twenty one percent of these primary breast cancer specimens exhibited the overexpression of p53 protein. Significant associations were found between p53 overexpression and younger age, high histologic grade and low content of estrogen and progesterone receptors. Identification of p53-positive breast carcinomas potentially represents a clinically useful indicator of breast cancer aggressiveness.
Neoplasma 02/1995; 42(5):235-7. · 1.44 Impact Factor
-
A Dziewulska-Bokiniec
[show abstract]
[hide abstract]
ABSTRACT: The possible association between cigarette smoking and the risk of benign breast disease (BBD) was assessed in a case-control study conducted in Gdańsk, Poland, between 1990 and 1994. The study compared 160 women with newly diagnosed BBD admitted to the Gdańsk Cancer Outpatients Clinic and 160 controls, women from outpatients clinics at the Medical University of Gdańsk. There was no convincing evidence of an association, either positive or negative, between various indicators of smoking habit (smoking status, number of cigarettes smoked per day, duration of smoking) and the risk of BBD. Slightly lower relative risks (RRs) of BBD in ex-smokers of 10 or more cigarettes per day (RR = 0.9; 95% confidence interval, CI: 0.4-2.2), and with duration of smoking > or = 20 years (RR = 0.8; 95% CI: 0.1-3.4), were also observed in current smokers (RR = 0.8; 95% CI: 0.4-1.5), and (RR = 0.8; 95% CI: 0.1-3.4), but these findings were not statistically significant.
Neoplasma 02/1995; 42(5):285-7. · 1.44 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: 54 patients (pts) with metastatic breast cancer were treated with aminoglutethimide 250 mg p.o. twice a day with hydrocortisone 40 mg p.o./day. All pts were postmenopausal, mean age 63 years, and pretreated with cytostatics and/or hormones. Dominant sites of metastases were: soft tissues 29 pts. bone 12 pts. lungs 6 pts. Objective responses were: 4 (7.4%) CR, 15 (27.8%) PR, 16 (29.6%) NC and 19 (35.2%) PD (UICC criteria). The response (CR + PR) at metastatic sites was: soft tissues 12 (41%), bone 4 (33%). The mean response duration was 15.0 months for CR; 10.2 for PR and 5.5 months for NC. The results of the study confirm that low--dose aminoglutethimide is an effective second-line hormonal treatment of advanced breast cancer.
Ginekologia polska 10/1994; 65(9):508-11. · 0.41 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Electrophoretic lipoprotein analyses were performed in 51 patients on tamoxifen and compared with those obtained from 33 newly diagnosed breast cancer patients and with data from the group of healthy women. A statistically significant lower rate of dyslipoproteinemia has been demonstrated in tamoxifen group in comparison with untreated patients; 23.5% vs. 54.5% (p < 0.01). Comparing the results of the latter group with normal subjects there was a significantly higher frequency of dyslipoproteinemia in untreated patients, 54.5% vs. 28.9% (p < 0.05). Our findings confirmed an estrogen-like influence of tamoxifen on lipoprotein profile in postmenopausal breast cancer patients.
Neoplasma 02/1994; 41(6):337-40. · 1.44 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Single determinations of serum CA 15-3 levels were performed by sandwich enzyme immunoassay in 160 women: 77 patients with nonmalignant breast tumors (64 had fibrocystic disease, 11 had fibroadenoma, 2 had intraductal papilloma) and 83 patients with primary breast cancer prior to any treatment; the cut-off limit was established at 30 U/ml. The overall diagnostic sensitivity and specificity of the CA 15-3 test was 19.3% and 94.8%, respectively. The positive and negative predictive values were 80.0% and 52.1%. The mean CA 15-3 value was significantly lower in patients with benign breast tumors as compared with the breast cancer group: 16.8 +/- 8.2 vs. 23.9 +/- 20.9 U/ml (p < 0.01) as well as the percentage of positive results of the test: 5.2% vs. 19.3% (p < 0.02). Serum CA 15-3 level in breast cancer patients correlated with: (1) clinical stage: a higher percentage of positive results was observed in patients with more advanced cancer: Stage I-0%, Stage II-10.6%, Stage III-29.6%, and Stage IV-100.0% according to UICC classification; the comparison of breast cancer patients with early stage of disease (I+II) and those with more advanced cancer (III+IV) revealed statistically significant (p < 0.01) difference in the mean serum CA 15-3 value (19.7 +/- 12.8 vs. 31.5 +/- 29.2 U/ml) as well as in the percentage of positive results (9.4% vs. 36.7%, p < 0.01); (2) the histological grading according to Bloom and Richardson: 5.41% of positivity was observed in low and intermediate grade cancers (I+II) vs. 66.7% in grade III (p < 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)
Neoplasma 01/1994; 41(4):213-6. · 1.44 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: The antiemetic efficacy of dexamethasone (Dexaven) was examined in patients with breast cancer during chemotherapy CMF (cyclophosphamide, methotrexate and 5-fluorouracil) in comparison with patients treated identically but without dexamethasone. Comparison of the revealed statistically significant lower nausea incidence (p < 0.025) and lower vomiting incidence (p < 0.025) in the group of patients receiving dexamethasone. The results confirm value of dexamethasone as an effective and safe antiemetic agent using during chemotherapy CMF.
Przegla̧d lekarski 01/1994; 51(5):203-5.
-
[show abstract]
[hide abstract]
ABSTRACT: Serum levels of total, free, HDL- and LDL-cholesterol were determined in 45 postmenopausal breast cancer women treated with tamoxifen (TAM) from 6 to 73 months (mean duration of TAM treatment was 21.3 months) as an adjuvant therapy after mastectomy, and in the control group of 33 breast cancer women at the time of diagnosis before any treatment. The mean age of patients was 63 years in the TAM treated group and 70 years in the untreated breast cancer patients. TAM treated patients were found to have significantly lower concentration of serum total cholesterol (5.43 mmol/l vs. 6.44 mmol/l; p < 0.02) and LDL-cholesterol (3.54 mmol/l vs. 4.32 mmol/l; p < 0.01). There were 8 (18%) hypercholesterolemic patients in the TAM treated group vs. 13 (39%) in the untreated breast cancer patients (p < 0.05). No statistically significant differences were observed in serum concentrations of free and HDL-cholesterol in the two evaluated groups. We conclude that the TAM-induced changes in serum lipid concentrations are due to an estrogen-like activity of the agent and the reduction of total and LDL-cholesterol level seems to be an additional advantage of TAM treatment.
Neoplasma 01/1994; 41(1):13-6. · 1.44 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: The serum of 47 previously untreated patients with Hodgkin disease (HD) was subjected to analysis for the presence and level of circulating immune complexes (IC) detected by the tests of inhibition of EA and EAC rosette formation. The control group included 100 healthy persons, health service workers. Significantly higher incidence and levels were demonstrated of EA IC and EAC IC in the serum of patients in relation to the control group (p < 0.001). No correlation, however, was found between the appearance of EA IC and EAC IC and the degree of clinical progression of the disease, and the presence or absence of systemic symptoms. The presence of IC in the serum of patients with HD is one link in the whole chain of various immunological disturbances existing in this disease, the starting point of which can be a pathologically changed cell of the lymphatic system.
Wiadomości lekarskie (Warsaw, Poland: 1960) 10/1992; 45(19-20):740-3.
-
[show abstract]
[hide abstract]
ABSTRACT: The presence of estrogen receptors (ER) has been studied in 70 patients with primary operable breast cancer. The tumors were graded histologically according to Bloom and Richardson criteria. A significant correlation was found between these two prognostic factors: the better--differentiated tumors (I + II histological grade) had significantly higher level of ER than that in the poor--differentiated tumors. Estrogen receptor content of primary breast cancer as a function of tumor grade can be useful in selection of the most efficient treatment modalities for individual patients.
Ginekologia polska 07/1992; 63(6):304-7. · 0.41 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Circulating immunological complexes (KI) are one of the parameters of humoral immunity. The occurrence of KI was found in the course of neoplastic diseases both in animals and humans. They are formed as a result of interaction of neoplastic antigens with specific tumor antibodies. Immunological complexes may be favourable or unfavourable to the modulation of effector mechanisms directed against neoplastic cells. In spite of extensive research, the participation of KI in immunological neoplastic response has not been clearly defined. The quantitative analysis of KI in the serum of patients with neoplasms revealed that the levels of KI may correlate with the degree of the progression of the disease, which has been shown for example in malignant melanoma, embryonal neuroma and carcinoma of the breast. The investigation of KI in the serum of patients with cervical carcinoma is rarely reported. The present paper shows 71 patients with squamous epithelial cervical carcinoma in various stages of progression, patients not receiving therapy. The evaluation of KI was made by means of two methods: test of inhibition of forming rosettes EA and inhibition of forming rosettes EAC. The authors of the few reports on the subject agree (which was also confirmed in our research) that the serum of patients with cervical carcinoma reveals the presence of KI. The frequency of occurrence and levels of KI may correlate with the degree of progression of a neoplastic process.
Ginekologia polska 03/1989; 60(2):90-4. · 0.41 Impact Factor
-
Nowotwory 02/1982; 32(3):171-3.
-
Archivum Immunologiae et Therapiae Experimentalis 02/1982; 30(1-2):57-62. · 2.54 Impact Factor
-
Wiadomości lekarskie (Warsaw, Poland: 1960) 06/1981; 34(10):815-9.
-
Polski tygodnik lekarski (Warsaw, Poland: 1960) 12/1979; 34(45):1751-3.
-
[show abstract]
[hide abstract]
ABSTRACT: In the blood serum of 71 patients before treatment with cervical carcinoma and in 100 healthy women from the health services working staff, the occurrence of circulating immunologic complexes (CI) has been estimated applying the rosette EA and EAC inhibition test. The presence of CI has been proved and the frequency of positive results increases together with the stage of advancement of the neoplastic process. It appears that the CI examination should be regarded as a significant parameter in monitoring the course of treatment.
Nowotwory 39(1):1-4.
-
[show abstract]
[hide abstract]
ABSTRACT: Applying the EA and EAC rosettes production inhibition method the appearance and levels of immunologic circulating complexes (CI) in the blood serum of 32 patients with cancer of the uterine cervix and in 100 healthy persons have been evaluated. Immunocomplexes have been examined prior to the initiation of brachytherapy and after three successive applications of radioactive cesium isotope (137Cs). Three successive application of the radioisotope contained and in the uterine probe have been used and a dose up to 2000 cGy in 16-18 hours given on each application. It has been shown that prior to treatment and in some stages of clinical advancement the levels of CI evaluated by two tests are significantly higher as compared with controls. Significant increase of CI levels after successive application of cesium has been also noted. The appearance of CI in patients with cervical cancer indicates the presence of tumor-specific and/or viral antigens in such patients. The elevation of CI levels after cesium application may be result of accelerated release of antigens in the course of brachytherapy.
Nowotwory 39(3-4):171-5.
